Page 50 - Anjali Singh

Aster DM Healthcare Q2 results: Consolidated revenue rises 17.7%

On a sequential basis, the company exhibited a 3.15 per cent increase in revenue along with EBITDA, which grew 21 per cent year-on-year

Biocon Biologics targets top three biosimilar spot: Shreehas Tambe

The opportunity ahead of us is massive because over the next 10 odd years until 2032, we see 55 blockbuster molecules and biologics going out or losing exclusivity, says Tambe

Biocon biologics receives marketing approval by MHRA for YESAFILI in UK

This approval follows the green light granted by the European Commission (EC) for marketing authorisation in the European Union (EU) back in September

50% surge in diabetes in individuals under 40 yrs of age, say experts

Prevalence of diabetes no longer confined to just older demographics, Vitamin B12 deficiency may be a cause

Biosimilars growth props up Biocon Q2 PAT by 168% to Rs 126 crore

The Generics segment, encompassing APIs and Generic Formulations, exhibited a 4 per cent year-on-year growth, reaching Rs 676 crore

Torrent, Zydus collaborate to bring liver disease treatment to India

Saroglitazar Mg received approval in March 2020 for NASH treatment and later expanded its indications to include NAFLD

Glenmark Pharmaceuticals receives USFDA approval for generic Prolixin

Prolixin is a prescription medication used to treat schizophrenia and other mental/mood disorders

Eris Lifesciences Q2 results: PAT at Rs 123.4 crore, revenue up 9.7%

On a sequential basis, the company exhibited an 8.29 per cent increase in revenue, along with a PAT which rose 30.17 per cent

Lupin introduces generic version of Zemuron Injection in United States

The newly introduced Rocuronium Bromide Injection is available in two formulations

Cipla announces transfer of Generics Business Undertaking to subsidiary

The generics business contributed 9.95 per cent of Cipla's turnover and 0.92 per cent of its net worth in the financial year ended March 31, 2023

Alkem Laboratories posts 87.85% increase in PAT, sales in India up by 5%

On a sequential basis, the company exhibited a 16.26 per cent increase in revenue

Alembic Pharmaceuticals' revenue surges 8.17%, PAT up 3.21% in Q2FY24

The API business reported a 10 percent growth in revenues, reaching Rs 322 crores in the quarter

Metropolis Healthcare PAT declines 12%, consolidated revenue up 2.7%

EBITDA stood at Rs 77.8 crore, declining 6.2 per cent year-on-year and growing 16.1 per cent sequentially

Egg freezing industry likely to touch Rs 25,000 crore mark in 10 years

According to industry experts, the egg-freezing market in India is still in its early stages but is poised for growth in the coming years

Dr Lal PathLabs Q2 results: Profit jumps 54.8%, revenue rises 12.63%

Dr Lal PathLab's share price rose to 3.30 per cent, ending the day's trade at Rs 2,455 apiece on the BSE

JK Tyre records net profit surge of nearly five-fold to Rs 242 cr in Q2FY24

On a sequential basis, the company exhibited a 4.83 per cent increase in revenue and the PAT increased by 57.35 per cent, respectively

Electric vehicle market set to be on full charge by 2025: ICRA report

The report highlights that the electric twowheeler (e2W) segment has emerged as a frontrunner, accounting for 85-90 per cent of total EV sales in FY23

Healthcare and pharma sector sees surge in high-value deals: Report

The Private Equity (PE) sector experienced a decline in both values and volumes compared to the previous quarter

SPARC completes enrollment in PROSEEK Global Phase 2 study of Parkinson's

PROSEEK, one of the largest phase-2 studies in early Parkinson's disease, encompassed 84 sites across the United States, Europe, and India

Sun Pharma and Zydus Lifesciences partner to market kidney drug Desidustat

Under this licensing agreement, Zydus has granted Sun Pharma semi-exclusive rights to co-market Desidustat in India